CN116583267A - 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用 - Google Patents
靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN116583267A CN116583267A CN202280006407.8A CN202280006407A CN116583267A CN 116583267 A CN116583267 A CN 116583267A CN 202280006407 A CN202280006407 A CN 202280006407A CN 116583267 A CN116583267 A CN 116583267A
- Authority
- CN
- China
- Prior art keywords
- targeted
- herpesvirus
- inactivated
- plaster
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001529453 unidentified herpesvirus Species 0.000 title claims abstract description 87
- 239000011505 plaster Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 title description 12
- 239000000203 mixture Substances 0.000 claims abstract description 45
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 24
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 20
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000284 extract Substances 0.000 claims abstract description 16
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000011780 sodium chloride Substances 0.000 claims abstract description 16
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 12
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000001630 malic acid Substances 0.000 claims abstract description 12
- 235000011090 malic acid Nutrition 0.000 claims abstract description 12
- 239000008213 purified water Substances 0.000 claims abstract description 12
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 11
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 11
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 11
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940085605 saccharin sodium Drugs 0.000 claims abstract description 11
- 229960004029 silicic acid Drugs 0.000 claims abstract description 11
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 11
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 11
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 11
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims abstract description 11
- 239000000600 sorbitol Substances 0.000 claims abstract description 11
- 235000010356 sorbitol Nutrition 0.000 claims abstract description 11
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 10
- 239000004317 sodium nitrate Substances 0.000 claims abstract description 10
- 235000010344 sodium nitrate Nutrition 0.000 claims abstract description 10
- 229940047908 strontium chloride hexahydrate Drugs 0.000 claims abstract description 10
- AMGRXJSJSONEEG-UHFFFAOYSA-L strontium dichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Sr]Cl AMGRXJSJSONEEG-UHFFFAOYSA-L 0.000 claims abstract description 10
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 10
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 10
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 9
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 9
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 9
- 229920013818 hydroxypropyl guar gum Polymers 0.000 claims abstract description 9
- -1 polyethylene Polymers 0.000 claims abstract description 9
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims abstract description 8
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims abstract description 8
- 229940052490 naringin Drugs 0.000 claims abstract description 8
- 229930019673 naringin Natural products 0.000 claims abstract description 8
- 239000004323 potassium nitrate Substances 0.000 claims abstract description 8
- 235000010333 potassium nitrate Nutrition 0.000 claims abstract description 8
- 229960004711 sodium monofluorophosphate Drugs 0.000 claims abstract description 8
- 239000001488 sodium phosphate Substances 0.000 claims abstract description 8
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims abstract description 8
- 235000019801 trisodium phosphate Nutrition 0.000 claims abstract description 8
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims abstract description 8
- 239000004698 Polyethylene Substances 0.000 claims abstract description 7
- 229920000573 polyethylene Polymers 0.000 claims abstract description 7
- 239000000230 xanthan gum Substances 0.000 claims abstract description 7
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 7
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 7
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 19
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 15
- 239000004615 ingredient Substances 0.000 claims description 14
- 239000006072 paste Substances 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 9
- 201000004946 genital herpes Diseases 0.000 claims description 9
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims description 8
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 206010035664 Pneumonia Diseases 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 208000030507 AIDS Diseases 0.000 claims description 7
- 239000000853 adhesive Substances 0.000 claims description 7
- 230000001070 adhesive effect Effects 0.000 claims description 7
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- 239000002562 thickening agent Substances 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- 206010059313 Anogenital warts Diseases 0.000 claims description 4
- 208000006558 Dental Calculus Diseases 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 208000007514 Herpes zoster Diseases 0.000 claims description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 3
- 241000701041 Human betaherpesvirus 7 Species 0.000 claims description 3
- 241000701027 Human herpesvirus 6 Species 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 206010044029 Tooth deposit Diseases 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000002474 experimental method Methods 0.000 claims description 3
- 239000010408 film Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 208000006379 syphilis Diseases 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 2
- 206010021531 Impetigo Diseases 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical class CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 claims description 2
- 206010029098 Neoplasm skin Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 229940024545 aluminum hydroxide Drugs 0.000 claims description 2
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 claims description 2
- 229940043256 calcium pyrophosphate Drugs 0.000 claims description 2
- 235000019821 dicalcium diphosphate Nutrition 0.000 claims description 2
- 230000000857 drug effect Effects 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229920000136 polysorbate Chemical class 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 108700004121 sarkosyl Chemical class 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 231100000588 tumorigenic Toxicity 0.000 claims 1
- 230000000381 tumorigenic effect Effects 0.000 claims 1
- 239000000686 essence Substances 0.000 abstract description 13
- 229940001516 sodium nitrate Drugs 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 description 8
- 206010000496 acne Diseases 0.000 description 7
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 241000450599 DNA viruses Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 208000024386 fungal infectious disease Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (28)
- 一种靶向灭活疱疹病毒膏贴组合物。其特征是,所述靶向灭活疱疹病毒膏贴组合物包含有贴、苹果酸0.08%~2.5%、硝酸钠0.05%~0.4%、两面针提取物0.1%~4.3%、纯净水适量、氯化锶六水合物0.1%~2.5%、凝血酸0.1%~2%、柚皮苷0.002%~2%、风轮草提取物0.01%~3%、单氟磷酸钠0.001%~1%、海盐0.01%~0.9%、硝酸钾0.05%~2%、氯化钠0.01%~0.9%、摩擦剂1%~50%、表面活性剂0.1%~3%、防腐剂0.05%~0.2%、香精0.5%~1.5%、甜味剂0.1%~1%、增稠剂0.05%~4%、保湿剂5%~21%、粘合剂0.05%~1%制成。
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物,其特征是,摩擦剂为碳酸钙、磷酸氢钙、水合硅石、焦磷酸钙、氢氧化铝、摩擦剂中一种或多种,其重量百分比为1%~50%;
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物,其特征是,表面活性剂为月桂醇硫酸脂钠、月桂酰肌氨酸、聚山梨醇酯类衍生物、表面活性剂中一种或多种,其重量百分比为0.1%~3%;
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物,其特征是,防腐剂为对羟基苯甲酸脂类、苯甲酸钠、防腐剂中一种或多种,其重量百分比为0.05%~0.2%;
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物,其特征是,香精为香精、薄荷、香精中一种或多种,其重量百分比为0.5%~1.5%;
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物,其特征是,甜味剂为糖精钠、甜味剂中一种或多种,其重量百分比为0.1%~1%;
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物,其特征是,增稠剂为羟 乙基纤维素、磷酸三钠、黄原胶、纤维素胶、增稠剂中一种或多种,其重量百分比为0.05%~4%;
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物,其特征是,保湿剂为山梨糖醇、木糖醇、聚乙二醇-8、保湿剂中一种或多种,其重量百分比为5%~21%;
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物,其特征是,粘合剂为羟丙基瓜儿胶、粘合剂中一种或多种,其重量百分比为0.05%~1%;
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物,其特征是,贴:膏贴、贴、膏、可以根据患处位置大小需要剪的薄贴、及各种薄贴。
- 根据权利要求1所述的靶向灭活疱疹病毒膏贴组合物,其特征是,其他:硝酸钠0.05%~0.4%、两面针提取物0.1%~4.3%、纯净水适量、氯化锶六水合物0.1%~2.5%、凝血酸0.1%~2%、柚皮苷0.002%~2%、风轮草提取物0.01%~3%、苹果酸0.08%~2.5%、贴、单氟磷酸钠0.001%~1%、海盐0.01%~0.9%、硝酸钾0.05%~2%、氯化钠0.01%~0.9%
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,靶向药物进入体内,特异性精准和疱疹病毒相结合发生作用,并在目标部位蓄积或释放有效成分,药物在贴的作用下在目标局部形成相对较高的浓度,在提高药效的同时灭活疱疹病毒,对身体正常细胞、正常组织无严重副作用。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,本发明的靶向药物包含有多种疾病的活性成分。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、 17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,疱疹病毒为选自以下的一种或多种:单纯疱疹病毒1型、单纯疱疹病毒2型、水痘带状疱疹、EB病毒、巨细胞病毒、人类疱疹病毒6型、人类疱疹病毒7型、人类疱疹病毒8型、艾滋病、生殖器疱疹、疱疹病毒
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,靶向灭活疱疹病毒膏贴组合物的制备方法在保护范围之内。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,膏指靶向药物。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,贴指靶向药物,
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,首创靶向灭活疱疹病毒膏贴药物在制药中的新用途也在保护范围之内。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,靶向灭活疱疹病毒膏贴组合物在制备靶向灭活疱疹病毒药物中的用途:红斑狼疮、炭疽病、天疱疮、皮肤肿瘤、掌趾脓疱病、肿瘤、单纯疱疹病毒、疱疹病毒、病毒、梅毒、清牙垢、新冠肺炎、艾滋病、尖锐湿 疣、肝炎、肺炎、疱疹为特征的疾病、病毒感染为特征的疾病都在保护范围之内。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,靶向灭活疱疹病毒膏贴组合物在制备靶向灭活疱疹病毒药物中有:艾滋病病毒、癌细胞、肿瘤、肿瘤细胞、致瘤因子、肝炎肺炎、病毒、疱疹病毒、真菌、病毒感染为特征疾病的活性成分。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,注射、介入治疗、靶向药物、感染部位给药、其他经皮给药。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,牙膏成分,辅料成分
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,靶向灭活疱疹病毒膏贴组合物可以制作水剂、溶液剂、注射剂、合剂、洗剂、搽剂、气雾剂、喷雾剂、散剂、丸剂、片剂、膜剂、胶囊剂、软膏剂、栓剂、糊剂各种不同的剂型药剂。任何仿制,都是进入保护范围之内。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,实施例实验的剂量是描述本发明,而不应经此限制本 发明的范围。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,实施例实验的成分是描述本发明,而不应经此限制本发明的范围。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,本发明为给患者最佳的治疗效果,不受实施例上成分剂量的限制,而是根据患者年龄、疱疹病毒感染情况、施用途径、以及所用包含特定药品的活性、病情严重程度及各种因素,因此,成分剂量方案可以广泛变化。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,成分剂量要求保护范围是0-100%。
- 根据权利要求1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28所述的靶向灭活疱疹病毒膏贴组合物,其特征是,靶向灭活疱疹病毒膏贴组合物治疗疱疹病毒比现有药物治疗时间少。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021104169343 | 2021-04-19 | ||
CN202110416934 | 2021-04-19 | ||
CNPCT/CN2021/000191 | 2021-09-18 | ||
CN2021000191 | 2021-09-18 | ||
PCT/CN2022/000056 WO2022206086A1 (zh) | 2021-04-19 | 2022-03-29 | 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116583267A true CN116583267A (zh) | 2023-08-11 |
CN116583267A8 CN116583267A8 (zh) | 2024-03-12 |
Family
ID=83457874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280006407.8A Pending CN116583267A (zh) | 2021-04-19 | 2022-03-29 | 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116583267A (zh) |
WO (1) | WO2022206086A1 (zh) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101057953A (zh) * | 2006-04-21 | 2007-10-24 | 陈祖辉 | 对付病毒感染疾患的多靶协同防治制剂 |
CN102525871B (zh) * | 2012-03-13 | 2013-04-10 | 常熟华港制药有限公司 | 用于预防和治疗复发性口疮的牙膏及制备方法 |
CN104258067B (zh) * | 2014-09-12 | 2017-08-29 | 皖南医学院 | 一种用于巴布剂的药物组合物、巴布剂及其制备工艺 |
CN105055230A (zh) * | 2015-08-11 | 2015-11-18 | 刘三猫 | 一种多功用的中药牙膏组合物及其牙膏和制备方法 |
CN108379139B (zh) * | 2018-03-07 | 2020-12-08 | 济川药业集团有限公司 | 一种防治口腔溃疡的牙膏及其制备方法和应用 |
-
2022
- 2022-03-29 WO PCT/CN2022/000056 patent/WO2022206086A1/zh active Application Filing
- 2022-03-29 CN CN202280006407.8A patent/CN116583267A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022206086A1 (zh) | 2022-10-06 |
CN116583267A8 (zh) | 2024-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9782426B2 (en) | Anti-viral therapeutic composition | |
US6410570B1 (en) | Methods of inactivating a virus and controlling viral replication | |
SA96160590B1 (ar) | تركيبة صيدلانية | |
CN104922130B (zh) | 一种用于治疗带状疱疹的凝胶剂及其制备方法 | |
WO1983001198A1 (en) | Method and composition for treating a patient suffering from interferon-susceptible disorder | |
US6579891B1 (en) | Agent and method for prevention and treatment of cancer in animals | |
KR20070054222A (ko) | 진통 작용이 있는 약제 조성물 | |
US20060074063A1 (en) | Pharmacological agent and method of treatment | |
CN111346081B (zh) | 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途 | |
AU781066B2 (en) | Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof | |
US4603122A (en) | Antiviral agent against herpes virus infections | |
CA1190148A (en) | Interferon-containing compositions | |
CN116583267A (zh) | 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用 | |
CN114588164B (zh) | 瑞马唑仑在预防围术期低体温和寒战中的应用 | |
US4499084A (en) | Ara-A Antiviral composition and method of administering the same | |
US6441009B1 (en) | Agent and method of preventing and treating heavy metal exposure and toxicity | |
US7618950B2 (en) | Method for treatment and prevention of herpes zoster by topical application | |
EP3693006A1 (en) | Nasal hepatitis b vaccine composition and method for producing same | |
US4829055A (en) | Method of treatment for herpes infections of external tissues | |
JPS58146509A (ja) | 医薬組成物 | |
CN107648249B (zh) | 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用 | |
CN107875165B (zh) | 一种治疗肿瘤放射治疗所致骨髓抑制的透皮给药制剂 | |
JPWO2004069261A1 (ja) | 抗ヘルペスウイルス外用製剤の製造方法 | |
CN116603012A (zh) | 一种中药凝胶及其制备方法和应用 | |
KR20230117106A (ko) | 제1 치료 활성 성분으로서의 백신을 제2 활성 성분과 조합하여 사용하여 암을 치료하기 위한 조성물 및 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI02 | Correction of invention patent application |
Correction item: Classification number Correct: A61K 36/758(2006.01)|A61K 9/70(2006.01)|A61P 31/22(2006.01)|A61K 36/53(2006.01)|A61K 31/7048(2006.01) False: A61K 8/97(2017.01) Number: 32-02 Page: The title page Volume: 39 Correction item: Classification number Correct: A61K 36/758(2006.01)|A61K 9/70(2006.01)|A61P 31/22(2006.01)|A61K 36/53(2006.01)|A61K 31/7048(2006.01) False: A61K 8/97(2017.01) Number: 32-02 Volume: 39 |
|
CI02 | Correction of invention patent application |